Malaria: A Global Battle with Rising Drug Resistance
The fight against malaria has reached a critical juncture. The World Health Organization (WHO) reveals that innovative tools, such as advanced nets and vaccines, have saved approximately 1 million lives and prevented 170 million cases in 2024. But amidst this success, a looming threat emerges: drug resistance.
The WHO's annual World Malaria Report highlights the impact of these new tools, which are now integrated into broader health systems. Since the introduction of the first malaria vaccines in 2021, 24 countries have embraced them in their routine immunization programs. Additionally, seasonal malaria chemoprevention has expanded, benefiting 54 million children in 2024, a significant leap from 0.2 million in 2012.
And here's the good news: 47 countries and one territory have successfully eliminated malaria, with Cabo Verde, Egypt, Georgia, Suriname, and Timor-Leste achieving this milestone in recent years.
But the battle is far from over. In 2024, malaria still claimed an estimated 610,000 lives, with 95% of these deaths occurring in the WHO African Region, primarily affecting children under five. The report uncovers a critical issue: antimalarial drug resistance is on the rise, threatening the goal of malaria elimination.
"While new prevention tools offer hope, we face an uphill battle," warns Dr. Tedros Adhanom Ghebreyesus, WHO Director-General. He emphasizes the challenges of increasing cases, drug resistance, and funding cuts, which could undo two decades of progress. However, he remains optimistic, stating, "With the right leadership and investment, a malaria-free world is within reach."
The report delves into the complexities of drug resistance, focusing on partial resistance to artemisinin derivatives, which have been crucial in malaria treatment after the failure of chloroquine and sulfadoxine-pyrimethamine. This resistance has been confirmed or suspected in eight African countries, raising concerns about the efficacy of artemisinin-based drugs.
The situation is dire: The Global Technical Strategy's target of reducing malaria deaths to 4.5 per 100,000 population seems distant, as the 2024 figure stands at 13.8 deaths per 100,000.
But here's where it gets controversial: The report identifies multiple challenges beyond drug resistance. Malaria parasites with gene deletions are compromising rapid diagnostic tests, and insecticide-treated nets are losing effectiveness due to pyrethroid resistance in 48 countries. The invasion of insecticide-resistant Anopheles stephensi mosquitoes in nine African countries further complicates urban malaria control.
And nature adds to the struggle: Extreme weather events alter mosquito habitats and transmission patterns, leading to more outbreaks. Conflict and instability disrupt health services, hindering access to care and timely treatment.
Funding is a critical issue: Global funding has plateaued, with $3.9 billion invested in 2024, falling short of the $9.3 billion target for 2025. Official Development Assistance (ODA) reductions have disrupted health systems, affecting surveillance and malaria surveys, and increasing the risk of delays in interventions.
Dr. Martin Fitchet, CEO of Medicines for Malaria Venture, advocates for new medicines with novel mechanisms to combat drug resistance. He highlights the development of Ganaplacide-Lumefantrine, a non-artemisinin combination therapy, as a promising step towards malaria resilience.
WHO calls for political commitments to be translated into tangible actions and resources, urging malaria-endemic countries to uphold the Yaoundé Declaration's pledge to end malaria deaths. The Big Push initiative aims to unite efforts and address current and future challenges to achieve a malaria-free world.
The question remains: Can we overcome drug resistance and secure a malaria-free future? The WHO report invites discussion and action, leaving readers with a sense of urgency and hope.
